Patents by Inventor Maude POIRIER

Maude POIRIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10538555
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 21, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
  • Patent number: 10450347
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: October 22, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20170369530
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 9, 2017
    Publication date: December 28, 2017
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9850283
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Publication number: 20170283462
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 5, 2017
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20170260237
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: September 11, 2014
    Publication date: September 14, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A.M. Cornelius
  • Publication number: 20160222060
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9315499
    Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: April 19, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
  • Patent number: 9308236
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9284310
    Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 15, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Francois Bilodeau, Mathieu Parisien, Maude Poirier, Cyrille Kuhn, Carl Thibeault, Thao Trinh
  • Publication number: 20150315180
    Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Application
    Filed: October 31, 2013
    Publication date: November 5, 2015
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Lee FADER, Francois BILODEAU, Mathieu PARISIEN, Maude POIRIER, Cyrille KUHN, Carl THIBEAULT, Thao TRINH
  • Publication number: 20150158861
    Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Application
    Filed: April 3, 2013
    Publication date: June 11, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
  • Publication number: 20140294898
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 2, 2014
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Publication number: 20110230465
    Abstract: Compounds of formula I: wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 22, 2011
    Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBH
    Inventors: Timothy STAMMERS, Xavier BARBEAU, Pierre BEAULIEU, Megan BERTRAND-LAPERLE, Christian BROCHU, Paul J. EDWARDS, Pasquale FORGIONE, Cédrickx GODBOUT, Oliver HUCKE, Marc-André JOLY, Serge LANDRY, Olivier LEPAGE, Julie NAUD, Marc PESANT, Martin POIRIER, Maude POIRIER, Bounkham THAVONEKHAM